Gastrointestinal endoscopy · 2010
Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial.
Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Altraif Ibrahim, Handoo Fayaz A, Aljumah Abdulrahman, Alalwan Abduljaleel, Dafalla Mutasim, Saeed Abdullah Mohamed, Alkhormi Abdulrahman, Albekairy Abdul Karim, Tamim Hani
Аннотация
BACKGROUND: Blood in the stomach and esophagus in patients with variceal bleeding often obscures the endoscopic view and makes endoscopic intervention difficult to perform. Erythromycin, a motilin agonist, induces gastric emptying.
OBJECTIVE: To assess the effect of erythromycin on endoscopic visibility and its outcome in patients with variceal bleeding.
DESIGN: Randomized, double-blind, placebo-controlled trial.
SETTING: Tertiary care hospital.
PATIENTS: Adult patients with liver cirrhosis presenting with hematemesis within the previous 12 hours.
INTERVENTION: Either 125 mg erythromycin or placebo administered intravenously 30 minutes before endoscopy.
MAIN OUTCOME MEASUREMENTS: Endoscopic visibility during index endoscopy and mean duration of procedure. SECONDARY OUTCOME MEASUREMENTS: Need for repeat endoscopy and blood transfusions within 24 hours, endoscopy-related complications, and length of hospital stay.
RESULTS: A total of 102 patients received either erythromycin or placebo (53 erythromycin and 49 placebo). Forty-seven patients in the erythromycin group and 43 in the placebo group had variceal bleeding and were considered for final analysis. A completely empty stomach was seen in 48.9% of the erythromycin group versus 23.3% of the placebo group (P<.01). Mean endoscopy duration was significantly shorter in the erythromycin group than in the placebo group (19.0 minutes vs 26.0 minutes, respectively; P<.005). Length of hospital stay was significantly shorter in the erythromycin group than in the placebo group (3.4 days vs 5.1 days, respectively; P<.002). The need for repeat endoscopy and the mean number of units of blood transfused did not differ significantly in the 2 groups. No adverse events were observed with erythromycin.
LIMITATIONS: Sample size not sufficient to measure the need for repeat endoscopy and survival benefit.
CONCLUSIONS: Erythromycin infusion before endoscopy in patients with variceal bleeding significantly improves endoscopic visibility and shortens the duration of the index endoscopy. (
CLINICAL TRIAL REGISTRATION NUMBER: NCT01060267.).
OBJECTIVE: To assess the effect of erythromycin on endoscopic visibility and its outcome in patients with variceal bleeding.
DESIGN: Randomized, double-blind, placebo-controlled trial.
SETTING: Tertiary care hospital.
PATIENTS: Adult patients with liver cirrhosis presenting with hematemesis within the previous 12 hours.
INTERVENTION: Either 125 mg erythromycin or placebo administered intravenously 30 minutes before endoscopy.
MAIN OUTCOME MEASUREMENTS: Endoscopic visibility during index endoscopy and mean duration of procedure. SECONDARY OUTCOME MEASUREMENTS: Need for repeat endoscopy and blood transfusions within 24 hours, endoscopy-related complications, and length of hospital stay.
RESULTS: A total of 102 patients received either erythromycin or placebo (53 erythromycin and 49 placebo). Forty-seven patients in the erythromycin group and 43 in the placebo group had variceal bleeding and were considered for final analysis. A completely empty stomach was seen in 48.9% of the erythromycin group versus 23.3% of the placebo group (P<.01). Mean endoscopy duration was significantly shorter in the erythromycin group than in the placebo group (19.0 minutes vs 26.0 minutes, respectively; P<.005). Length of hospital stay was significantly shorter in the erythromycin group than in the placebo group (3.4 days vs 5.1 days, respectively; P<.002). The need for repeat endoscopy and the mean number of units of blood transfused did not differ significantly in the 2 groups. No adverse events were observed with erythromycin.
LIMITATIONS: Sample size not sufficient to measure the need for repeat endoscopy and survival benefit.
CONCLUSIONS: Erythromycin infusion before endoscopy in patients with variceal bleeding significantly improves endoscopic visibility and shortens the duration of the index endoscopy. (
CLINICAL TRIAL REGISTRATION NUMBER: NCT01060267.).
Предметные рубрики MeSH
Dose-Response Relationship, DrugDouble-Blind MethodEndoscopy, GastrointestinalErythromycinEsophageal and Gastric VaricesFemaleFollow-Up StudiesGastric EmptyingGastrointestinal AgentsGastrointestinal HemorrhageHemostasis, EndoscopicHumansInjections, IntravenousMaleMiddle AgedPreoperative CareProspective StudiesTreatment Outcome